Single Photon Emission Computed Tomography (SPECT)

Single Photon Emission Computed Tomography (SPECT)

Global Single Photon Emission Computed Tomography (SPECT) Market to Reach US$3.3 Billion by 2030

The global market for Single Photon Emission Computed Tomography (SPECT) estimated at US$2.1 Billion in the year 2023, is expected to reach US$3.3 Billion by 2030, growing at a CAGR of 7.1% over the analysis period 2023-2030. Cardiology Application, one of the segments analyzed in the report, is expected to record a 8.1% CAGR and reach US$1.3 Billion by the end of the analysis period. Growth in the Oncology Application segment is estimated at 7.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$738.1 Million While China is Forecast to Grow at 9.7% CAGR

The Single Photon Emission Computed Tomography (SPECT) market in the U.S. is estimated at US$738.1 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$399.5 Million by the year 2030 trailing a CAGR of 9.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.8% and 6.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.8% CAGR.

Global Single Photon Emission Computed Tomography (SPECT) Market - Key Trends & Drivers Summarized

Single Photon Emission Computed Tomography (SPECT) is a sophisticated imaging technique widely used in the field of nuclear medicine. This modality allows for three-dimensional visualization of metabolic and physiological processes in the body by detecting gamma rays emitted from radioactive tracers. These tracers are typically injected into the bloodstream and accumulate in specific tissues, organs, or cellular receptors, depending on the type of tracer used. SPECT is particularly valuable in cardiology, oncology, and neurology, providing critical insights into conditions such as coronary artery disease, tumors, and neurological disorders like epilepsy and Alzheimer`s disease. The ability of SPECT to provide functional imaging distinguishes it from other imaging modalities like CT and MRI, which primarily offer anatomical information.

Technological advancements have significantly enhanced the capabilities and applications of SPECT. The integration of SPECT with computed tomography (SPECT/CT) has revolutionized the field by combining functional and anatomical imaging in a single session. This hybrid approach improves diagnostic accuracy and allows for better localization and characterization of abnormalities. Recent developments in detector technology, such as the use of cadmium zinc telluride (CZT) detectors, have increased the sensitivity and resolution of SPECT systems, enabling faster acquisition times and reduced radiation doses for patients. Furthermore, advancements in software algorithms for image reconstruction and processing have improved the quality and quantitative accuracy of SPECT images. These innovations have expanded the utility of SPECT in both clinical practice and research, making it an indispensable tool in modern healthcare.

The growth in the SPECT market is driven by several factors. Increasing prevalence of chronic diseases such as cardiovascular diseases, cancer, and neurological disorders is a major driver, as these conditions often require detailed functional imaging for diagnosis and management. Technological advancements, including the development of hybrid SPECT/CT systems and improvements in detector materials and image processing algorithms, have significantly enhanced the clinical utility and adoption of SPECT. Additionally, the growing emphasis on personalized medicine and the need for precise diagnostic tools to tailor treatments to individual patients are fueling demand for advanced imaging modalities like SPECT. The rising geriatric population, which is more susceptible to chronic diseases, further expands the potential market for SPECT. Lastly, the increasing availability of radiopharmaceuticals and the expansion of nuclear medicine facilities worldwide are also contributing to market growth. These factors collectively underscore the dynamic and evolving nature of the SPECT market.

Select Competitors (Total 45 Featured) -

• GE Healthcare
• Cardinal Health, Inc.
• Bruker Corporation
• Agfa-Gevaert NV
• Analogic Corporation
• Biosensors International Group Ltd.
• Koninklijke Philips N.V.
• Bracco SpA
• Digirad Corporation
• Bracco Imaging SpA
• CMR Naviscan Corporation
• BC Technical, Inc.
• DDD-Diagnostic A/S
• Cubresa Inc.
• Beijing Hamamatsu Photon Techniques, Inc.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.